Researchers recapitulate pathological condition of retinal diseases on a chip

Approximately 80% of all sensory input is received via the eyes, so suffering from chronic retinal diseases that lead to blindness causes a significant decrease in the quality of life (QOL). And because retinal diseases are most common among the elderly, developing pathological analysis and treatments for retinal diseases has become an urgent issue in super-aging countries such as Japan.

Although evaluation of drug candidates against retinal diseases has been done on animal models, serious concerns arise regarding the ethics and costs in addition to the limitations of translating data from animal models to clinical settings.

In vitro cell culture models, an alternative to animal models, enable researchers to investigate specific molecules-of-interest and simply recapitulate complex and chronic conditions. Although studies on organ-on-a-chip for drug discovery have recently been extensively carried out, the organ-on-a-chip approach that targets the ocular tissues has been rarely investigated.

A joint research team from the Graduate Schools of Engineering and Medicine at Tohoku University has recapitulated a pathological condition of retinal diseases on a chip. They first cultured human retinal cells and vascular endothelial cells, mimicking the outermost structure of the retina.

When retinal cells were exposed to hypoglycemic and hypoxic conditions after the cells had grown up, endothelial cells were found to migrate to the side of retinal cells to damage them. This process partially recapitulates neovascularization in wet-type age-related macular degeneration (AMD).

The research team believes the developed organ-on-a-chip could be used for disease modeling and drug screening as an alternative to animal models.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how antimicrobial exposure affects Parkinson’s disease risk